Background
Sermorelin [GHRH(1-29)-NH₂] is a synthetic 29-amino acid fragment corresponding to the biologically active N-terminus of endogenous growth hormone-releasing hormone (GHRH). Unlike exogenous GH, sermorelin stimulates the pituitary to produce and release its own GH in a pulsatile, physiologically regulated pattern — preserving the negative feedback mechanisms that prevent GH excess.
The somatopause — progressive decline in GH/IGF-1 secretion with aging — contributes to sarcopenia, increased adiposity, reduced bone density, and metabolic dysfunction. Vittone and colleagues at the National Institute on Aging evaluated whether nightly sermorelin administration could restore pulsatile GH secretion and reverse body composition changes associated with aging in a controlled trial of healthy elderly men.
Methods
22 healthy men (mean age 65 years, range 61–72) with documented low-normal GH levels participated in a double-blind, placebo-controlled crossover trial. Nightly subcutaneous injections of GHRH(1-29) at 2 µg/kg were administered for 3 months. Body composition was assessed by DEXA; GH dynamics by 24-hour sampling; IGF-1 by immunoassay.
Key Findings
GH Axis Restoration:
- Mean 24-hour GH concentration increased 2.3-fold vs. placebo
- IGF-1: 117 → 182 ng/mL (+55%, p < 0.01), approaching younger adult reference ranges (150–250 ng/mL)
- GH pulse frequency preserved at approximately 6 pulses/24 hours — pulsatility augmented without becoming tonic
- Pituitary responsiveness to sermorelin was maintained throughout the 3-month period (no tachyphylaxis observed)
Body Composition:
| Parameter | GHRH(1-29) | Placebo | p-value |
|---|---|---|---|
| Lean body mass change (kg) | +1.8 | −0.2 | < 0.05 |
| Fat mass change (kg) | −1.5 | +0.4 | < 0.05 |
| Percent body fat | −1.9% | +0.6% | < 0.05 |
- Lean body mass increase of 1.8 kg attributable to GH-stimulated IGF-1 anabolic signaling
- Fat mass reduction of 1.5 kg consistent with GH’s lipolytic effects on adipose tissue
- Net body weight change minimal (lean gains offset fat loss) — body composition improvement without weight change
Metabolic Parameters:
- Fasting glucose: no significant change
- Fasting insulin: slight reduction (trend, not significant) — consistent with improved insulin sensitivity from body composition changes
- Resting energy expenditure: +6% (trend) consistent with lean mass increase
Sermorelin’s Mechanism Advantage
Unlike exogenous GH replacement:
- Sermorelin stimulates endogenous pituitary GH rather than bypassing it
- IGF-1 elevation triggers normal feedback inhibition of GH (prevents accumulation)
- Physiological pulsatility preserved — GH peaks mimic overnight GH surges of younger adults
- Pituitary remains functional and responsive — no axis suppression after discontinuation
Clinical Significance
- Physiological GH restoration: The 55% IGF-1 increase brought most subjects into the younger adult reference range — a clinically meaningful restoration of the GH axis
- Lean/fat composition shift: Both anabolic (lean mass +1.8 kg) and catabolic (fat −1.5 kg) components of GH action were captured in the 3-month window
- Safety advantage: Preserved pulsatility and feedback mechanism limits the risk of GH-related adverse effects (edema, carpal tunnel, glucose impairment) compared to direct GH injection
- Elderly tolerability: No serious adverse events in a population at higher baseline metabolic risk
Limitations
- Small sample size (n=22); insufficient to detect effects on bone density or functional outcomes
- 3-month duration; body composition changes from GH axis restoration may require 6–12 months to reach maximal magnitude
- Male-only cohort; female GH dynamics during menopause differ significantly
- Crossover design with 3-month washout period may be insufficient if carry-over effects on IGF-1 persist
- No exercise or dietary control; lifestyle factors could confound body composition outcomes